Baxter Home
Conditions Therapies Products Services About Baxter
Nederlands French Contact Us
 

Working at Baxter

Working at Baxter
What we do

Baxter is a global diversified healthcare company that develops products and therapies to make a meaningful difference in the lives of people with haemophilia, kidney disease, immune disorders and other chronic and acute conditions. 

Baxter employs 2,000 people in Belgium, has a Research & Development Centre in Nivelles and a very large manufacturing plant in Lessines as well as a European distribution centre. Belux headquarters are located in Brussels.

The company operates in three segments:  BioScience develops biopharmaceuticals, biosurgery products, vaccines and blood collection products and technologies. 
Medication Delivery provides intravenous solutions and specialty products used for fluid replenishment, anaesthesia, nutrition, pain management, antibiotic therapy and chemotherapy.  Renal develops products and services to treat end-stage kidney disease.

Our vision

Baxter’s vision is to be: recognized and trusted worldwide; a preferred partner in improving the quality of and access to healthcare; an innovator in science and technology; the leader in our markets; a high quality investment; a rewarding place to work and develop; and socially responsible members of our communities.

Our culture

The company’s culture is grounded in an employee base that has a passion to innovate and drive for solutions, personal accountability for results and integrity, eagerness to learn and continuously improve, uncompromising dedication to quality, relentless focus on rapid and disciplined action and respect for the diverse contributions of all.

Baxter’s approximately 45,000 employees in more than 100 countries around the world are connected by their enduring commitment to save and sustain lives. It is this higher purpose that binds us as a company and as global citizens.  

For additional information, please visit www.baxter.com.

 
Copyright & Legal Disclaimer  |  Privacy  |   Print this page